keyword
MENU ▼
Read by QxMD icon Read
search

Rav

keyword
https://www.readbyqxmd.com/read/28881052/asunaprevir-and-daclatasvir-for-recurrent-hepatitis-c-after-liver-transplantation-a-japanese-multicenter-experience
#1
Toru Ikegami, Yoshihide Ueda, Nobuhisa Akamatsu, Kohei Ishiyama, Ryoichi Goto, Akihiko Soyama, Kaori Kuramitsu, Masaki Honda, Masahiro Shinoda, Tomoharu Yoshizumi, Hideaki Okajima, Yuko Kitagawa, Yukihiro Inomata, Yonson Ku, Susumu Eguchi, Akinobu Taketomi, Hideki Ohdan, Norihiro Kokudo, Mitsuo Shimada, Katsuhiko Yanaga, Hiroyuki Furukawa, Shinji Uemoto, Yoshihiko Maehara
The safety and efficacy of an IFN-free regimen using asunaprevir (ASV) and daclatasvir (DCV) for recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) has not been evaluated in Japan. A multicenter study of LT recipients (n=74) with recurrent HCV genotype 1b infection treated with ASV-DCV for 24 weeks was performed. Medical history was positive for pegylated-interferon and ribavirin (Peg-IFN/RBV) in 40 (54.1%) patients, and for simeprevir (SMV) with Peg-IFN/RBV 12 (16.2%) patients. Resistance-associated variants (RAVs) were positive at D168 (n=1) in the NS3, and at L31 (n=4), Y93 (n=4), and L31/Y93 (n=1) in the NS5A region of the HCV genome...
September 7, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28874040/direct-acting-antiviral-agents-in-korean-patients-with-chronic-hepatitis-c-and-hemophilia-who-are-treatment-na%C3%A3-ve-or-treatment-experienced
#2
Hyun Woong Lee, Ki Young Yoo, Joung Won Won, Hyung Joon Kim
Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. Methods: Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21; 1a, n=5) and four patients were genotype 2a/2b. Among 21 patients with genotype 1b, Y93H resistance-associated variants (RAVs) were detected in three patients (14.3%). We evaluated sustained virologic response (SVRs) at 12 weeks, as well as relapse and safety...
September 15, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28851606/clinical-evaluation-of-a-newly-developed-automated-massively-parallel-sequencing-assay-for-hepatitis-c-virus-genotyping-and-detection-of-resistance-association-variants-comparison-with-a-line-probe-assay
#3
Narathon Manee, Nipa Thongbaiphet, Ekawat Pasomsub, Wasun Chantratita
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. Recently, HCV was classified into 6 major genotypes (GTs) and 67 subtypes (STs). Efficient genotyping has become an essential tool for prognosis and indicating suitable treatment, prior to starting therapy in all HCV-infected individuals. The widely used genotyping assays have limitation with regard to genotype accuracy. This study was a comparative evaluation of exact HCV genotyping in a newly developed automated-massively parallel sequencing (MPS) system, versus the established Line probe assay 2...
August 26, 2017: Journal of Virological Methods
https://www.readbyqxmd.com/read/28836992/real-life-prevalence-of-resistance-associated-variants-against-non-structural-protein-5a-inhibitors-and-efficiency-of-daclatasvir%C3%A2-%C3%A2-asunaprevir-therapy-in-korean-patients-with-genotype-1b-hepatitis-c
#4
Jung Hwan Yu, Jung Il Lee, Kwan Sik Lee, Ja Kyung Kim
BACKGROUND: Direct-acting antivirals (DAAs) for chronic hepatitis C (CHC) treatment are tolerable and highly effective in a shorter period of time than before. However, resistance-associated variants (RAVs) can affect the efficacy of DAAs. The aim of this study was to investigate the real-life prevalence of RAVs against non-structural protein 5A (NS5A) inhibitors in Korean patients with genotype 1b chronic hepatitis C. METHODS: All consecutive patients with CHC genotype 1b who underwent a RAV test at a single referral hospital were enrolled...
August 24, 2017: Virology Journal
https://www.readbyqxmd.com/read/28815329/efficacy-and-safety-of-ledipasvir-sofosbuvir-with-ribavirin-in-chronic-hepatitis-c-patients-who-failed-daclatasvir-asunaprevir-therapy-pilot-study
#5
Yoshiiku Kawakami, Hidenori Ochi, Clair Nelson Hayes, Michio Imamura, Masataka Tsuge, Takashi Nakahara, Yoshio Katamura, Hiroshi Kohno, Hirotaka Kohno, Keiji Tsuji, Shintaro Takaki, Nami Mori, Yohji Honda, Keiko Arataki, Shoichi Takahashi, Shinsuke Kira, Toru Tamura, Kazunari Masuda, Toshio Nakamura, Masaya Kikkawa, Kazuaki Chayama
BACKGROUND: In Japan, daclatasvir (DCV) and asunaprevir (ASV) therapy was the first IFN-free treatment to be approved, and thousands of patients have since been successfully treated, with an SVR rate of around 90%. The converse, however, is that around 10% of patients fail to achieve viral eradication and must be retreated using a different approach. This study is to evaluate treatment efficacy of ledipasvir/sofosbuvir and ribavirin in patients who failed to respond to DCV and ASV therapy...
August 16, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28679980/selection-of-regimens-for-patients-with-hepatitis-c-virus-genotype-serotype-discrepancy
#6
Shinji Katsushima, Tatsuro Kobata, Toshiki Komeda, Seiko Hamada, Kouki Chikugo, Shigeharu Nakano, Tsubasa Shimogama, Ken Kumagai, Yoshiyuki Ohta, Bunji Endoh, Naoki Esaka, Satoru Iwamoto, Katsuhiro Kasahara, Nobuko Shima, Yoshinori Mizumoto
In the present study, the usefulness of the resistance-associated variant (RAV) analysis to select direct acting antiviral (DAA) drugs for patients with hepatitis C virus (HCV) genotype/serotype discrepancy was evaluated. The core-genotype and serotype were determined in the 559 patients recruited in the study. The RAV analysis and NS5B-genotype determination were performed in the eight patients who exhibited a genotype/serotype discrepancy. One of these patients exhibited a core-genotype 1b/serotype 2, and detection by RAV analysis was possible in this patient...
2017: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://www.readbyqxmd.com/read/28667225/using-patient-reported-outcome-measures-proms-to-promote-quality-of-care-and-safety-in-the-management-of-patients-with-advanced-chronic-kidney-disease-pro-track-project-a-mixed-methods-project-protocol
#7
Olalekan Lee Aiyegbusi, Derek Kyte, Paul Cockwell, Tom Marshall, Mary Dutton, Anita Slade, Neil Marklew, Gary Price, Rav Verdi, Judi Waters, Keeley Sharpe, Melanie Calvert
INTRODUCTION: Advanced chronic kidney disease (CKD) has a major effect on the quality of life and health status of patients and requires accurate and responsive management. The use of electronic patient-reported outcome measures (ePROMs) could assist patients with advanced pre-dialysis CKD, and the clinicians responsible for their care, by identifying important changes in symptom burden in real time. We report the protocol for 'Using Patient-Reported Outcome measures (PROMs) to promote quality of care and safety in the management of patients with Advanced Chronic Kidney Disease' (PRO-trACK) project, which will explore the feasibility and validity of an ePROM system for use in patients with advanced CKD...
June 30, 2017: BMJ Open
https://www.readbyqxmd.com/read/28657143/emergence-of-drug-resistance-associated-variants-and-changes-in-serum-lipid-profiles-in-sofosbuvir-plus-ledipasvir-treated-chronic-hepatitis-c-patients
#8
Hiromi Kan, Michio Imamura, Yoshiiku Kawakami, Kana Daijo, Yuji Teraoka, Fumi Honda, Yuki Nakamura, Kei Morio, Tomoki Kobayashi, Takashi Nakahara, Yuko Nagaoki, Tomokazu Kawaoka, Masataka Tsuge, Hiroshi Aikata, Clair Nelson Hayes, Daiki Miki, Hidenori Ochi, Yoji Honda, Nami Mori, Shintaro Takaki, Keiji Tsuji, Kazuaki Chayama
Combination of sofosbuvir plus ledipasvir therapy has been expected to enhance sustained virological response (SVR) rates in hepatitis C virus (HCV) genotype 1 chronic infected patients. We analyzed the emergence of drug resistance-associated variants (RAVs) in treatment failure and changes in lipid profiles in sofosbuvir/ledipasvir-treated patients. A total of 176 patients with chronic HCV genotype 1 infection without decompensated liver cirrhosis were treated with sofosbuvir/ledipasvir for 12 weeks. NS5A and NS5B RAVs were determined by either Invader assay or direct sequencing...
June 28, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28642765/genome-wide-identification-of-ap2-erf-transcription-factors-in-cauliflower-and-expression-profiling-of-the-erf-family-under-salt-and-drought-stresses
#9
Hui Li, Yu Wang, Mei Wu, Lihong Li, Cong Li, Zhanpin Han, Jiye Yuan, Chengbin Chen, Wenqin Song, Chunguo Wang
The AP2/ERF transcription factors (TFs) comprise one of the largest gene superfamilies in plants. These TFs perform vital roles in plant growth, development, and responses to biotic and abiotic stresses. In this study, 171 AP2/ERF TFs were identified in cauliflower (Brassica oleracea L. var. botrytis), one of the most important horticultural crops in Brassica. Among these TFs, 15, 9, and 1 TFs were classified into the AP2, RAV, and Soloist family, respectively. The other 146 TFs belong to ERF family, which were further divided into the ERF and DREB subfamilies...
2017: Frontiers in Plant Science
https://www.readbyqxmd.com/read/28634481/genome-wide-analysis-of-the-rav-family-in-soybean-and-functional-identification-of-gmrav-03-involvement-in-salt-and-drought-stresses-and-exogenous-aba-treatment
#10
Shu-Ping Zhao, Zhao-Shi Xu, Wei-Jun Zheng, Wan Zhao, Yan-Xia Wang, Tai-Fei Yu, Ming Chen, Yong-Bin Zhou, Dong-Hong Min, You-Zhi Ma, Shou-Cheng Chai, Xiao-Hong Zhang
Transcription factors play vital roles in plant growth and in plant responses to abiotic stresses. The RAV transcription factors contain a B3 DNA binding domain and/or an APETALA2 (AP2) DNA binding domain. Although genome-wide analyses of RAV family genes have been performed in several species, little is known about the family in soybean (Glycine max L.). In this study, a total of 13 RAV genes, named as GmRAVs, were identified in the soybean genome. We predicted and analyzed the amino acid compositions, phylogenetic relationships, and folding states of conserved domain sequences of soybean RAV transcription factors...
2017: Frontiers in Plant Science
https://www.readbyqxmd.com/read/28614668/cryptic-micro-heteroresistance-explains-m-tuberculosis-phenotypic-resistance
#11
John Z Metcalfe, Elizabeth Streicher, Grant Theron, Rebecca E Colman, Christopher Allender, Darrin Lemmer, Rob Warren, David M Engelthaler
BACKGROUND: Minority resistant M. tuberculosis subpopulations can be associated with phenotypic resistance, but are poorly detected by Sanger sequencing or commercial molecular diagnostic assays. The role of targeted next generation sequencing (NGS) in resolving these minor variant subpopulations is unclear. METHODS: We utilized Single Molecule-Overlapping Reads (SMOR), a targeted NGS approach that dramatically reduces sequencing error, to analyze primary cultured isolates phenotypically resistant to rifampin, fluoroquinolones, or aminoglycosides, but for which Sanger sequencing found no resistance-associated variants (RAVs) within respective resistance determining regions (RDRs) (Study Group)...
June 14, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28569206/virology-analysis-in-hcv-genotype-1-infected-patients-treated-with-the-combination-of-simeprevir-and-tmc647055-ritonavir-with-and-without-ribavirin-and-jnj-56914845
#12
Leen Vijgen, Kim Thys, An Vandebosch, Pieter Van Remoortere, René Verloes, Sandra De Meyer
BACKGROUND: In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high sustained virologic response 12 weeks after actual end of treatment (SVR12) in chronic hepatitis C virus (HCV) genotype 1-infected patients. SVR12 rates were generally lower in the 2-DAA regimen SMV + TMC647055/RTV with or without ribavirin. The objective of this study was to identify and characterise pre-existing and emerging resistance-associated variants (RAVs) in patients enrolled in study TMC647055HPC2001...
May 31, 2017: Virology Journal
https://www.readbyqxmd.com/read/28560477/daclatasvir-and-asunaprevir-in-hemodialysis-patients-with-hepatitis-c-virus-infection-a-nationwide-retrospective-study-in-japan
#13
Goki Suda, Norihiro Furusyo, Hidenori Toyoda, Yoshiiku Kawakami, Hiroki Ikeda, Michihiro Suzuki, Keiko Arataki, Nami Mori, Keiji Tsuji, Yoshio Katamura, Koichi Takaguchi, Toru Ishikawa, Kunihiko Tsuji, Noritomo Shimada, Atsushi Hiraoka, Sho Yamsaki, Masato Nakai, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Mineo Kudo, Atsushi Nagasaka, Ken Furuya, Yoshiya Yamamoto, Kanji Kato, Yoshiyuki Ueno, Etsuko Iio, Yasuhito Tanaka, Masayuki Kurosaki, Takashi Kumada, Kazuaki Chayama, Naoya Sakamoto
BACKGROUND: Hepatitis C virus (HCV) infection is common in hemodialysis patients and worsens their prognosis, while antiviral therapy options are limited. Recently, clinical trial and real-world, small-scale studies have reported excellent responses to direct-acting antivirals in patients with advanced chronic kidney diseases. However, real-world, large-scale data were lacking. This large multicenter analysis included HCV-infected hemodialysis patients receiving combination therapy with a nonstructural protein 5A (NS5A) inhibitor, daclatasvir (DCV), and a protease inhibitor, asunaprevir (ASV)...
May 30, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28522095/the-reduction-of-central-sleep-apnoea-severity-in-the-left-lateral-position-is-not-due-to-an-improvement-in-cardiac-haemodynamics-in%C3%A2-patients-with-chronic-heart-failure
#14
Egidio Traversi, Davide Rossi, Roberto Maestri, Francesca Olmetti, Maria Teresa La Rovere, Gian Domenico Pinna
OBJECTIVE: The severity of central sleep apnoea (CSA), a common comorbidity in patients with chronic heart failure (CHF) and reduced ejection fraction, markedly decreases from the supine to the lateral sleeping position, with no difference between the left and right positions. The mechanisms responsible for this beneficial effect have not yet been elucidated. METHODS: We tested the hypothesis that CSA attenuation in the left lateral position is due, at least in part, to an improvement in cardiac haemodynamics...
June 2017: Sleep Medicine
https://www.readbyqxmd.com/read/28511781/correlation-of-right-atrial-enlargement-on-ecg-to-right-atrial-volume-by-echocardiography-in-patients-with-pulmonary-hypertension
#15
John D Allison, Francisco Yuri Macedo, Ihab Rafic Hamzeh, Yochai Birnbaum
Previous attempts to validate ECG criteria for right atrial (RA) enlargement (RAE) have been limited by sample sizes and lack of accepted standards for measuring RA size. New guidelines have recommended that RA volume (RAV) be used to determine RA size. Since these guidelines were released, no studies have been published that correlate RAE by ECG to RAV using the new standards. We aimed to validate previously proposed ECG criteria for RAE, commonly called P pulmonale, and to establish whether a correlation exists between P wave amplitudes and RAV as determined by echocardiogram in patients from the pulmonary hypertension (PHT) clinic...
April 22, 2017: Journal of Electrocardiology
https://www.readbyqxmd.com/read/28499845/exploring-resistance-pathways-for-first-generation-ns3-4a-protease-inhibitors-boceprevir-and-telaprevir-using-bayesian-network-learning
#16
Lize Cuypers, Pieter Libin, Yoeri Schrooten, Kristof Theys, Velia Chiara Di Maio, Valeria Cento, Maja M Lunar, Frederik Nevens, Mario Poljak, Francesca Ceccherini-Silberstein, Ann Nowé, Kristel Van Laethem, Anne-Mieke Vandamme
Resistance-associated variants (RAVs) have been shown to influence treatment response to direct-acting antivirals (DAAs) and first generation NS3/4A protease inhibitors (PIs) in particular. Interpretation of hepatitis C virus (HCV) genotypic drug resistance remains a challenge, especially in patients who previously failed DAA therapy and need to be retreated with a second DAA based regimen. Bayesian network (BN) learning on HCV sequence data from patients treated with DAAs could provide insight in resistance pathways against PIs for HCV subtypes 1a and 1b, in a similar way as applied before for HIV...
May 9, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/28489763/naturally-occurring-drug-resistance-associated-variants-to-hepatitis-c-virus-direct-acting-antiviral-agents-in-treatment-naive-hcv-genotype-1b-infected-patients-in-china
#17
Zhanyi Li, Ying Zhang, Ying Liu, Xiaoqiong Shao, QiuMin Luo, Qingxian Cai, Zhixin Zhao
The direct-acting antiviral agents (DAAs) have drastically improved the prognosis of hepatitis C virus (HCV) patients. However, the resistance-associated variants (RAVs) to DAAs may hamper treatment. There was a lack of data on the prevalence of pre-exist RAVs in Chinese HCV-infected patients. We performed nested PCR assays on 74 HCV genotype 1b-infected patients to amplify HCV viral regions of NS3, NS5A, and NS5B to investigate the prevalence of RAVs to DAAs in treatment-naive HCV genotype1b-infected patients in China...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28463753/a-genotype-independent-full-genome-reverse-transcription-protocol-for-hcv-genotyping-and-resistance-testing
#18
Andreas Walker, Matthias Bergmann, Jennifer Camdereli, Rolf Kaiser, Nadine Lübke, Jörg Timm
BACKGROUND: HCV treatment options and cure rates have tremendously increased in the last decade. Although a pan-genotype HCV treatment has recently been approved, most DAA therapies are still genotype specific. Resistance-associated variants (RAVs) can limit the efficacy of DAA therapy and are associated with increased risk for therapy failure. With the approval of DAA regimens that recommend resistance testing prior to therapy, correct assessment of the genotype and testing for viruses with RAVs is clinically relevant...
April 10, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28457119/the-importance-of-trans-thoracic-echocardiographic-suprasternal-view-in-the-diagnosis-and-treatment-follow-up-of-pulmonary-emboli
#19
Moshe Rav Acha, Aharon Medina, David Rosenmann, Naama Md, Marc W Klutstein, Adi Butnaru, Giora Weisz
No abstract text is available yet for this article.
January 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28441362/real-world-experiences-with-the-combination-treatment-of-ledipasvir-plus-sofosbuvir-for-12-weeks-in-hcv-genotype-1-infected-japanese-patients-achievement-of-a-sustained-virological-response-in-previous-users-of-peginterferon-plus-ribavirin-with-hcv-ns3-4a-inhibitors
#20
Tatsuo Kanda, Shin Yasui, Masato Nakamura, Eiichiro Suzuki, Makoto Arai, Yoshihiko Ooka, Sadahisa Ogasawara, Tetsuhiro Chiba, Tomoko Saito, Yuki Haga, Koji Takahashi, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Akinobu Tawada, Hitoshi Maruyama, Fumio Imazeki, Naoya Kato, Osamu Yokosuka
The aim of this study was to characterize the treatment response and serious adverse events of ledipasvir plus sofosbuvir therapies in Japanese patients infected with hepatitis C virus (HCV) genotype 1 (GT1). This retrospective study analyzed 240 Japanese HCV GT1 patients treated for 12 weeks with 90 mg of ledipasvir plus 400 mg of sofosbuvir daily. Sustained virological response at 12 weeks post-treatment (SVR12) was achieved in 236 of 240 (98.3%) patients. Among treatment-naïve patients, SVR12 was achieved in 136 of 138 (98...
April 25, 2017: International Journal of Molecular Sciences
keyword
keyword
42976
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"